Combining AzurRx BioPharma‘s investigational therapy MS1819 with standard pancreatic enzyme replacement therapy (PERT) can improve fat absorption in cystic fibrosis…
Articles by Marisa Wexler, MS
People with cystic fibrosis (CF) experience many barriers that limit their participation in physical activity, ranging from a lack…
The European Commission (EC) agreed to expand use of Vertex’s Kaftrio (ivacaftor/tezacaftor/elexacaftor), in combination with Kalydeco (ivacaftor), to…
Blocking an enzyme called phosphodiesterase-4 (PDE4) may be useful in the treatment of dry mouth and cystic fibrosis (CF),…
A European Medicines Agency (EMA) committee favors extending the label for Kaftrio (ivacaftor/tezacaftor/elexacaftor), in combination with Kalydeco (ivacaftor), to treat cystic…
Bronchitol (mannitol), an inhaled mucus-clearing treatment for cystic fibrosis (CF), is now commercially available in the U.S., according…
The first two patients have been dosed in the Phase 2b OPTION 2 extension study evaluating MS1819 in treating…
A Phase 1/2 clinical trial, called CYPHY, to evaluate the phage therapy YPT-01 in treating chronic Pseudomonas aeruginosa infections…
Children with cystic fibrosis (CF) who live in more socioeconomically disadvantaged areas of the U.S. tend to have worse…
Health Canada is reviewing an application that seeks the approval of Trikafta, a triple combination reported to treat 90%…